Literature DB >> 30187920

Development and analytical validation of a radioimmunoassay for the quantification of alpha1 -proteinase inhibitor in serum and feces from the common marmoset (Callithrix jacchus).

Joseph Cyrus Parambeth1, Jonathan A Lidbury1, Jan S Suchodolski1, Jörg M Steiner1.   

Abstract

BACKGROUND: The objective of this study was to develop and analytically validate a radioimmunoassay (RIA) for the measurement of alpha1 -proteinase inhibitor (α1 -PI) concentrations in serum and feces from the common marmoset.
METHODS: Serum samples (n = 30) and 3-day fecal samples (n = 30) were obtained from healthy marmosets. An RIA was established and validated by determination of sensitivity, working range, dilutional parallelism, spiking recovery, and intra- and interassay variability. A reference interval for mα1 -PI in serum and feces was established.
RESULTS: Sensitivity and upper limit of the working range were 0.75 and 100.62 μg/L, respectively. Observed-to-expected (O/E) ratios for serial dilutions ranged from 89.9% to 123.0% (mean ±SD: 106.0 ± 11.5%) for 8 serum samples, and from 90.6% to 132.7% (mean ±SD: 107.6 ± 19.2%) for 4 fecal samples. O/E ratios for spiking recovery ranged from 97.6% to 104.4% (mean ±SD: 101.3 ± 3%) for 4 serum samples, and from 97.5% to 101.4% (mean ±SD: 99.2 ± 1.8%) for 4 fecal samples and 3 different spiking concentrations. Coefficients of variation (CV) for intra-assay variability for 8 serum samples ranged from 1.7% to 10.6% and 2.2% to 5.1% in the 8 fecal samples. The interassay CV for eight serum samples ranged from 1.3% to 9.9%, and from 1.0% to 6.7% in the 8 fecal samples. The reference interval in serum was determined to be 1047-1484 μg/L. The reference interval in serum was determined to be 1047-1484 μg/L. The reference interval for the 3-day mean fecal concentration, and 3-day maximum fecal concentration were determined to be 32.4-124.4 μg/g and 39.1-158.7 μg/g of feces, respectively.
CONCLUSION: The developed assay is sensitive, linear, accurate, precise, and reproducible. Further studies are needed to determine the clinical utility of this assay.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  immunoassay; new world primate; protein-losing enteropathy

Mesh:

Substances:

Year:  2018        PMID: 30187920      PMCID: PMC6234082          DOI: 10.1111/jmp.12375

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  15 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.

Authors:  Marie-Anne Valentin; Shenglin Ma; An Zhao; François Legay; Alexandre Avrameas
Journal:  J Pharm Biomed Anal       Date:  2011-03-29       Impact factor: 3.935

3.  Purification and partial characterization of α1-proteinase inhibitor in the common marmoset (Callithrix jacchus).

Authors:  Joseph Cyrus Parambeth; Jan S Suchodolski; Jörg M Steiner
Journal:  Res Vet Sci       Date:  2015-02-11       Impact factor: 2.534

4.  Evaluation of fecal α1-proteinase inhibitor concentrations in cats with idiopathic inflammatory bowel disease and cats with gastrointestinal neoplasia.

Authors:  Kathrin F Burke; John D Broussard; Craig G Ruaux; Jan S Suchodolski; David A Williams; Jörg M Steiner
Journal:  Vet J       Date:  2012-12-08       Impact factor: 2.688

5.  Fecal alpha1-proteinase inhibitor concentration in dogs with chronic gastrointestinal disease.

Authors:  K F Murphy; A J German; C G Ruaux; J M Steiner; D A Williams; E J Hall
Journal:  Vet Clin Pathol       Date:  2003       Impact factor: 1.180

6.  Serum alpha1-proteinase inhibitor concentrations in healthy dogs--method validation and determination of reference interval and intra-individual variation.

Authors:  Romy M Heilmann; Craig G Ruaux; Iwan A Burgener; Jennifer D Hern; Jan S Suchodolski; Jörg M Steiner
Journal:  Vet Clin Pathol       Date:  2013-04-23       Impact factor: 1.180

Review 7.  Marmoset models commonly used in biomedical research.

Authors:  Keith Mansfield
Journal:  Comp Med       Date:  2003-08       Impact factor: 0.982

8.  Purification and partial characterization of feline alpha1-proteinase inhibitor (falpha1-PI) and the development and validation of a radioimmunoassay for the measurement of falpha1-PI in serum.

Authors:  Kathrin Fetz; Craig G Ruaux; Jörg M Steiner; Jan S Suchodolski; David A Williams
Journal:  Biochimie       Date:  2004-01       Impact factor: 4.079

9.  Bioanalytical method validation: An updated review.

Authors:  Gaurav Tiwari; Ruchi Tiwari
Journal:  Pharm Methods       Date:  2010-10

10.  Serum albumin and body weight as biomarkers for the antemortem identification of bone and gastrointestinal disease in the common marmoset.

Authors:  Victoria K Baxter; Gillian C Shaw; Nathaniel P Sotuyo; Cathy S Carlson; Erik J Olson; M Christine Zink; Joseph L Mankowski; Robert J Adams; Eric K Hutchinson; Kelly A Metcalf Pate
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.